Background
==========

The field of radiotherapy (RT) is rapidly evolving with new advanced treatment techniques and improved imaging. Implementation of magnetic resonance imaging (MRI) for segmentation together with sophisticated image guided radiotherapy (IGRT) techniques based on implanted fiducials has resulted in improved accuracy and precision in RT for prostate cancer \[[@B1]-[@B3]\]. A workflow based solely on MR, i.e. from prostate delineation to treatment planning and delivery, has been proposed and shown to reduce systematic uncertainties considerably compared to a conventional CT/MR-based workflow \[[@B4]\]. Evidence from prostate cancer radiotherapy trials shows that dose-escalation improves outcome \[[@B5]-[@B8]\] with limited increase in toxicity \[[@B9],[@B10]\]. The latter is partly due to a reduction of the CTV-PTV margins compared with those applied when positioning the treatment beams based on skin marks or on bony structures \[[@B11]\]. In addition, inter-fraction and intra-fraction prostate motion have been studied extensively during recent years \[[@B12]-[@B14]\]. However, the optimal CTV-PTV margin in a specific setting is still debated \[[@B15]\]. When the margin is reduced to as small as 3 mm, adequate coverage of at least larger prostates seems to be jeopardized \[[@B16],[@B17]\].

The CTV-PTV margin should not only take setup variations and tumour motion into account but also include any changes in the shape and size of the CTV \[[@B18]\]. Changes in prostate morphology during radiotherapy are not well studied. There is some evidence that prostate size increases slightly during the first week(s) after start of conventionally fractionated RT and then decreases substantially during treatment and shrinks to below baseline by the end of treatment \[[@B19],[@B20]\].

Hypo-fractionated RT of prostate cancer has earned increased attention due to a proposed low α/β value, close to 1.5 Gy \[[@B21],[@B22]\]. The application of higher fraction doses might result in a larger change in prostate shape and size as compared with conventional fractionation, since prostate swelling is known to occur during brachytherapy \[[@B23],[@B24]\].

The aim of the present study was to measure any changes in prostate size during a course of extreme hypo- fractionation delivered with external beam technique by using sequential MRI scanning before, during and at the end of the RT course. A cohort of patients from a Swedish multicentre trial (HYPO-RT-PC), studying extreme hypo-fractionation, was used for the study.

Methods
=======

Patients
--------

Twenty patients treated with extreme hypo-fractionation were included in the present study. All patients were recruited from an on-going Scandinavian prospective randomized phase III trial (HYPO-RT-PC), which compares extreme hypo-fractionation with conventional fractionation in intermediate risk prostate cancer patients \[[@B25]\]. This study was approved by the local ethics committee (Division of Oncology, Department of Clinical Sciences, Lund University) and is performed according to the Helsinki Declaration of 1975, (revised in 2000). Inclusion criteria are: age \< 75 years, WHO performance status 0--2, intermediate risk prostate cancer with clinical category T1c-T3a with one of the following risk factors: 1) T3a, 2) Gleason ≥ 7 or 3) PSA \> 10 μg/L. PSA shall be \< 20 μg/L and a biopsy-proven adenocarcinoma without any signs of spread distally or to lymph nodes are also required. Any earlier treatment for prostate cancer, previous hormonal therapy, other serious diseases (including prior malignant disease), conditions that could prevent implantation of markers into the prostate or signs of metastatic disease are exclusion criteria. Patient characteristics for the cohort in the present study are given in Table [1](#T1){ref-type="table"}.

###### 

Patient baseline characteristics (n = 20)

  **Age**                                  
  --------------------------------------- -------------
  Median (range)                          68 (59--73)
  **Tumour stage**                         
  T1c                                     17
  T2                                      3
  **Gleason score**                        
  6                                       3
  7                                       14
  8                                       3
  **iPSA (ng/mL)**                         
  Mean (SD)                               10.2 (4.5)
  **Prostate volume (cm**^**3**^**)\***    
  Mean (SD)                               73 (30)

\*As segmented on CT.

Treatment
---------

In the HYPO-RT-PC study, patients are randomized between either conventional fractionation (39 × 2.0 Gy = 78.0 Gy given once a day, five days per week) or to an experimental arm with an extreme hypo-fractionated regimen (7 × 6.1 Gy = 42.7 Gy given every other weekday, and always including two weekends without RT). The trial arms are equieffective assuming α/β = 3 Gy, neglecting any influence of the difference in total treatment time. Both 3D-conform radiotherapy (3D-CRT) and IMRT/VMAT techniques are allowed. Hormonal treatment is not permitted.

Radiotherapy procedure according to the HYPO-RT-PC study protocol
-----------------------------------------------------------------

Three gold markers were implanted into the prostate for daily image guidance at least three weeks before the treatment planning CT to avoid post-implant oedema of the gland. Target and OAR definitions were according to ICRU \[[@B18],[@B26],[@B27]\]. The CTV, i.e. prostate (no seminal vesicles), was segmented as visualised on the treatment-planning CT (slice thickness ≤ 3 mm). CT defined prostate segmentation is mandatory according to the study protocol but MRI is recommended as an aid for target delineation. The PTV includes CTV with a 7 mm isotropic 3D-margin. The CT-based CTV volume for the patients included in the present study was already defined within the clinical trial by three different senior radiation oncologists.

Sequential MRI scanning for CTV delineation
-------------------------------------------

The patients were imaged with a Siemens Espree 1.5 T MR scanner (Siemens Medical, Erlangen, Germany) using a body coil and a T2 weighted high-resolution 3D sequence with axial slices (slice thickness 1.7-3.3 mm). This MRI sequence is used in clinical routine as aid for the CT-based target definition. The patients were placed in supine position with a leg fixation device on a flat table-top insert during the MR imaging, i.e. in the same position as for RT.

MRI scans were performed at baseline (MRI~baseline~) when the patient came for treatment-planning CT, in the middle (MRI~mid~, EQD2~3~ = 33 Gy) and at the end of treatment (MRI~end,~ EQD2~3~ = 67 Gy). The MRI studies were transferred to the treatment planning system (Nucletron Oncentra, ver 4.0) where the prostate was delineated in each MRI slice by the same radiation oncologist (AG). This delineation was done in a blinded fashion. The volume, as calculated by the treatment planning system, was registered for each CTV~MRI~. In addition, the maximum extension of the delineated prostate on the MRIs was measured in the three principal directions, i.e. left-right (x~max~), anterior-posterior (y~max~) and cranial-caudal (z~max~) to estimate any changes in size in the three directions. The x~max~, y~max~ and z~max~ values are hence the sides of the smallest rectangular prism which precisely contains the segmented prostate.

To test whether the average change in prostate volume at the various time points was significant, a standard two-sided t-test was used. A p-value \< 0.05 was considered significant.

Results
=======

Segmented absolute prostate volumes together with relative prostate volume changes vs. the baseline MRI volume are given in Table [2](#T2){ref-type="table"}. The results are also presented graphically in Figure [1](#F1){ref-type="fig"}. The prostate volumes measured on the treatment-planning CT averaged 23% larger than those delineated on the baseline MRI (MRI~baseline~). The difference was statistically significant, p = 0.0001.

![**Relative prostate volume compared to baseline (MRI**~**baseline**~**) at MRI**~**mid**~**(EQD2**~**3**~ **= 33 Gy) (squares) and at MRI**~**end**~**(EQD2**~**3**~ **= 67 Gy) (circles) for patients 1--20.**](1748-717X-9-22-1){#F1}

###### 

**Prostate volumes in descending order as segmented on the treatment planning CT and on the MR images before radiotherapy (MRI**~**baseline**~**), in the middle of the treatment (MRI**~**mid**~**) and at the end of treatment (MRI**~**end**~**)**

  **Pat \#**              **CT**    **MRI**~**baseline**~   **MRI**~**mid**~    **MRI**~**end**~                              
  -------------------- ------------ ----------------------- ------------------ ------------------ -------------- ------------ ------------
  1                        35.3     1.579                   22.4                      26.7        1.191              27.2     1.217
  2                        44.5     1.369                   32.5                      38.6        1.187              34.9     1.074
  3                        33.8     0.999                   33.9                      39.0        1.151              33.1     0.976
  4                        47.8     1.105                   43.3                      47.5        1.098              46.2     1.067
  5                        45.8     1.054                   43.4                      48.9        1.126              48.7     1.122
  6                        64.8     1.455                   44.5                      53.3        1.198              44.1     0.991
  7                        71.6     1.597                   44.8                      49.8        1.112              46.6     1.040
  8                        43.5     0.906                   48.0                      48.7        1.015              48.0     1.000
  9                        79.4     1.648                   48.2                      55.5        1.152              54.4     1.129
  10                       73.0     1.511                   48.4                      48.9        1.011              50.1     1.037
  11                       59.4     1.102                   53.9                      60.8        1.128              55.2     1.023
  12                       57.0     1.037                   54.9                      65.3        1.189              64.4     1.172
  13                     \--^\*^    \--^\*^                 57.2                      66.6        1.166              62.2     1.089
  14                       83.8     1.196                   70.1                      88.7        1.265              78.0     1.112
  15                       99.0     1.347                   73.5                      80.0        1.088              74.1     1.008
  16                       79.4     1.066                   74.5                      95.5        1.282              96.2     1.291
  17                       96.5     1.145                   84.3                      96.8        1.148             \--^‡^    \--^‡^
  18                      105.8     1.242                   85.2                      96.3        1.131             101.4     1.190
  19                      106.2     1.021                   104.0                    116.8        1.123             115.6     1.112
  20                      153.7     1.045                   147.1                    155.0        1.054             152.9     1.040
  **Mean**               **72.7**   **1.233**               **60.7**                **68.9**      **1.141**        **64.9**   **1.089**
  SD                       30.4     0.232                   28.7                      31.3        0.070              31.9     0.084
  **p-value**^**†**^    **0.0001**  **0.0004**              **\-\--**             **\<0.0001**    **\<0.0001**    **0.0008**  **0.0002**

Relative volumes and p-values are in relation to MRI~baseline~.

\*Prostate was not segmented on CT as the patient had a hip prosthesis.

^‡^Missing data, MRI not performed.

^†^Paired t-test.

The median time (range) elapsed from MRI~baseline~ to MRI~mid~ and from MRI~baseline~ to MRI~end~ was 8 (6--9) days and 16 (15--17) days, respectively. According to the sequential MRI scanning analyses, extreme hypo-fractionation caused a 14% mean relative volume increase (p \< 0.0001) at MRI~mid~. The mean volume increase was still present at the time of the last treatment fraction (9% at MRI~end~, p = 0.0002). There was no significant difference in mean relative volume change between prostates above vs. below the median CTV size, neither at MRI~mid~ (p = 0.30) nor at MRI~end~ (p = 0.20).

The maximum prostate dimensions (x~max~, y~max~ and z~max~) as defined above were unchanged in the lateral direction but increased in the anterior-posterior and cranial-caudal directions by 2--3 mm for MRI~mid~ or MRI~end~ as compared with baseline (see Table [3](#T3){ref-type="table"} for details). Corresponding data for "small" versus "large" prostate baseline volumes are presented in Table [4](#T4){ref-type="table"}.

###### 

**Average change in maximum prostate extension in lateral (∆x**~**max**~**), anterior--posterior (∆y**~**max**~**) and cranial--caudal (∆z**~**max**~**) direction (mean values and 95% CI)**

                          **∆x**~**max**~**(mm)**   **P**   **∆y**~**max**~**(mm)**   **p**    **∆z**~**max**~**(mm)**   **p**
  ----------------------- ------------------------- ------- ------------------------- -------- ------------------------- --------
  MR~mid~--MR~baseline~   0.2 (−1.1--1.5)           0.72    3.3 (1.8--4.8)            0.0002   2.5 (1.0--3.9)            0.0019
  MR~end~--MR~baseline~   0.3 (−0.9--1.4)           0.60    2.0 (0.5--3.4)            0.010    2.0 (0.8--3.1)            0.0029
  MR~end~--MR~mid~        0.1 (−0.8--0.9)           0.89    −1.4 (−2.7--−0.1)         0.036    −0.6 (−1.7--0.6)          0.32

###### 

**Average change in maximum prostate extension in lateral (∆x**~**max**~**), anterior--posterior (∆y**~**max**~**) and cranial--caudal (∆z**~**max**~**) direction for "small"/"large" prostate volumes, i.e. below/above median MRI**~**baseline**~**volume (=50 cm**^**3**^**)**

                          **∆x**~**max**~**(mm)**   **p**   **∆y**~**max**~**(mm)**   **p**   **∆z**~**max**~**(mm)**   **p**
  ----------------------- ------------------------- ------- ------------------------- ------- ------------------------- -------
  MR~mid~--MR~baseline~   −0.5/1.0                  0.24    3.3/3.3                   0.98    1.9/3.0                   0.44
  MR~end~--MR~baseline~   −0.1/0.7                  0.44    1.3/2.8                   0.29    1.9/2.0                   0.88
  MR~end~--MR~mid~        0.0/0.0                   0.41    −0.2/−0.1                 0.24    0.0/−0.1                  0.34

Discussion
==========

Variations in prostate size during a course of radiotherapy using conventional fractionation have been studied previously. Generally these studies have shown an overall prostate volume reduction at end of treatment (without any anti-hormonal treatment) as compared to baseline although with an initial volume increase \[[@B19],[@B20],[@B28]\]. Based on the relative position of implanted electro-magnetic transponders, King *et al*. showed that the prostate size increases transiently (mean 6.1%) during the first week(s) after start of conventional RT (total dose 81 Gy, 1.8 Gy/fraction) and then shrinks to below baseline by the end of treatment. The decrease in mean prostate volume was 10.9% from the first to the final day of RT. Using MRI, Nichol *et al*. studied changes in prostate size during conventionally fractionated RT (total dose 79.8 Gy, 1.9 Gy/fraction) in 25 patients. They reported a prostate volume decrease by 0.5%/fraction. Based on CT scanning at start and at the last week of RT (total dose 76 Gy, 2.0 Gy/fraction), Sanguineti *et al*. reported a mean decrease in prostate volume of 7% in 14 patients without any anti-hormonal treatment.

To our knowledge there are no earlier studies on how extreme hypo-fractionation affects the prostate volume during radiotherapy. The extreme hypo-fractionation regimen used in our study lead to a significant increase in prostate volume after three treatment fractions (EQD2~3~ = 33 Gy). This increase was still apparent at the end of treatment after six fractions (EQD2~3~ = 67 Gy). Our observations indicate that the enlargement of the CTV is both larger than that known for conventional therapy and stays enlarged during the whole treatment course. This could be an important factor to take into account when choosing margin size.

When using daily imaging for set up correction, a minimum margin size between 1.5-3 mm to compensate for intra-fraction motion of the prostate has been proposed as adequate \[[@B15],[@B16]\]. Our results indicate that a margin extension of similar magnitude (covering the 95% CIs in Table [3](#T3){ref-type="table"}) could be needed to take prostate swelling into account during extreme hypo-fractionation. The analysis of prostate distension showed that the prostate seemed to swell most profoundly in the anterior-posterior and cranial-caudal directions. This might indicate that a margin reduction towards the rectum should be applied with caution, especially during extreme hypo-fractionation. The difference in prostate expansion in cranial-caudal and anterior-posterior directions on one hand and lateral direction on the other hand could be due to the pelvic side wall acting as an anatomic barrier \[[@B19]\].

Prostate swelling during brachytherapy is well known \[[@B23],[@B24]\], and thus one could expect larger swelling when using hypo-fractionation than during conventional radiotherapy treatment. Our study supports this and sparks concerns that larger treatment margins are indicated with this kind of regimen as compared with conventional treatment, especially if prostate segmentation is based on MRI only. MRI-based contouring at baseline resulted in a CTV volume that was about 20% smaller than the volume generated in the original treatment-planning CT which is in concordance with an earlier study by Smith *et al.*\[[@B29]\] who found an average difference of 16%. Inferior soft tissue contrast on CT as compared to MRI increases inter-observer variability in CT-based target definition which can partly explain this difference in volume between CT and MRI. The fact that current clinical evidence in prostate cancer radiotherapy is generated from CT-based target definition, implies that great care has to be taken to compensate for prostate swelling if the segmentation and treatment planning process is performed with MR-only \[[@B30]\]. We also looked at whether patients with larger prostate glands experienced more swelling than patients with smaller glands. No such difference in relative prostate volume change was observed.

To minimize multi-observer variation in prostate segmentation as well as MRI-sequence based errors \[[@B31]\], the same radiation oncologist did the delineation in a blinded fashion on the same MRI-sequence at each time-point. The fact that the prostate increased in volume at mid-treatment as compared to baseline for all patients supports that this is due to a true treatment induced swelling and not a methodological error. One could also argue that image guided set-up correction would cope with this change in prostate shape during the course of treatment. However, this correction usually involves three markers implanted centrally in the prostate gland, and thus it is probably adequate for prostate motion but less adequate for taking changes in the outer boundaries of the gland into consideration. Re-contouring of the prostate volume followed by re-planning before each fraction could be needed when using narrow margins (≤ 3 mm).

Conclusions
===========

Our study indicates that the prostate swells significantly during external radiotherapy when using extreme hypo-fractionation. This seems to be an important factor when defining margin size for extreme hypo-fractionation schedules for prostate cancer to minimize the risk of treatment failure when using narrow margins. In order to take prostate swelling into account when using extreme hypo-fractionation, we conclude that up to 2 mm extra margin could be needed if prostate segmentation is based only on MRI. Adaptive radiotherapy with re-planning before each fraction, which would also take changes in prostate shape into consideration, would be optimal.

We are planning a larger study on prostate volume change within the frame of the HYPO-RT-PC trial also including conventional fractionation for comparison.
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